Sagimet Biosciences
CA - San Mateo
BiotechnologyFocus: Drugs targeting the fatty acid synthase enzyme
Sagimet Biosciences is a life sciences company focused on Drugs targeting the fatty acid synthase enzyme.
Infectious DiseasesOncologyMetabolic Diseases
Open Jobs
3
Pipeline & Clinical Trials
TVB-2640 - 50 mg
Non-alcoholic SteatohepatitisClinical Trials (1)
NCT05835180A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function
Phase 1Denifanstat
HealthyClinical Trials (1)
NCT07216313A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants
Phase 1[14C]-TVB-2640
Healthy VolunteersClinical Trials (1)
NCT05657834Open-label Study of the Absorption, Metabolism, and Excretion of [14C]TVB-2640 Following a Single Oral Dose in Healthy Male Subjects
Phase 1TVB-2640
Solid Malignant TumorClinical Trials (1)
NCT02223247A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors
Phase 1TVB-3567
AcneClinical Trials (1)
NCT06989840Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne
Phase 1Phase 1
Clinical Trials (1)
NCT05743621Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
Phase 13-V Bioscience-2640
Metabolic SyndromeClinical Trials (1)
NCT02948569Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome
Phase 1/2Clinical Trials (1)
NCT04906421Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)
Phase 2TVB-2640
KRAS Gene MutationClinical Trials (1)
NCT03808558Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas
Phase 2TVB-2640 25 mg
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)Clinical Trials (1)
NCT03938246Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Phase 2denifanstat
MASLDClinical Trials (1)
NCT06692283A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH
Phase 3Denifanstat
MASHClinical Trials (1)
NCT06594523A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis
Phase 3Open Jobs (3)
Interview Prep Quick Facts
Portfolio: 12 clinical trials
Open Roles: 3 active jobs
Hiring Trend
Stable
3
Open Roles
+0
Added
-0
Filled/Removed
Based on last 4 crawl cycles